Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
NAT2 slow genotype carriers had an OR of 3.59 (95% CI: 2.62-4.93) for BC when exposed to aromatic amines and an OR of 2.07 (95% CI: 1.36-3.15) when exposed to PAHs.
|
28403014 |
2018 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
NAT2 acetylator phenotype modifies urinary bladder cancer risk following exposures to arylamine carcinogens such as 4-aminobiphenyl.
|
29180287 |
2018 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The phase II enzymes N-acetyltransferase 2 (NAT2), glutathione S-transferases M1 (GSTM1), and T1 (GSTT1) and the single nucleotide polymorphism (SNP) rs11892031[A/C] reported to be associated with bladder cancer in genome-wide association studies were genotyped.
|
28696895 |
2017 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The majority of BC patients were slow acetylators (NAT2 genotype).
|
29211353 |
2017 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Most relevant for bladder cancer risk were GSTM1 and UGT1A but not NAT2.
|
28696839 |
2017 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The nuclear matrix protein 22 (NMP22), bladder cancer-4 (BLCA-4), and total level proteins NMP22 and BLCA-4 (NMBL) in BC patients with genetic predisposition NAT2 (classified as slow acetylators, SA), DNA damage (8-OHdG), and detoxification by isoenzyme GST<i>π</i> activity were measured.
|
28929116 |
2017 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Polymorphic xenobiotic metabolizing enzymes such as N-acetyltransferase 2 (NAT2) or glutathione S-transferase M1 (GSTM1) are known to modulate bladder cancer risk.
|
28696897 |
2017 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
rs1495741 as a tag single nucleotide polymorphism of N-acetyltransferase 2 acetylator phenotype associates bladder cancer risk and interacts with smoking: A systematic review and meta-analysis.
|
27495060 |
2016 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, the NAT2 slow phenotypes also significantly increased the risk of bladder cancer in smokers (OR, 0.75; 95% CI, 0.62-0.90; P = .002).
|
26585839 |
2016 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
The apparent differential associations for phenotypic and genetic measures of acetylation statuses with bladder cancer risk may reflect dual functions of NAT2 in bladder carcinogenesis because the former only measures the capacity of carcinogen detoxification pathway while the latter represents both carcinogen activation and detoxification pathways.
|
27223070 |
2016 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The NAT2 slow genotype, together with GSTM1 null genotype facilitated the development of bladder cancer in almost all ethnic groups.
|
26854433 |
2016 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
N-acetyltransferase 2 slow genotype together with tobacco smoking increases bladder cancer risk.
|
25376209 |
2015 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study attempted to explore the correlation between NAT2 slow acetylation and bladder cancer risk through a meta-analysis of published case-control studies.
|
26681036 |
2015 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Numerous studies have shown that slow NAT2 haplotypes are associated with increased urinary bladder cancer risk and increased risk of anti-tuberculosis drug-induced hepatotoxicity.
|
24524665 |
2014 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In our analysis of smoking and bladder cancer, the tests for multiplicative interaction seemed to more commonly identify susceptibility loci with associations in never smokers, whereas the additive interaction analysis identified more loci with associations among smokers-including the known smoking and NAT2 acetylation interaction.
|
24662972 |
2014 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The NAT2 slow genotype also significantly increased the risk of bladder cancer in heavy smokers (OR 8.57, 95 % CI 1.82-40.25; p < 0.05).
|
22961351 |
2013 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The association of slow NAT2 genotypes with bladder cancer risk was most prominent in the Venezuelan study group.
|
23277078 |
2013 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings confirm established or suspected occupational risk factors but not the anticipated role of NAT2 slow acetylation in bladder cancer.
|
24092628 |
2013 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The main RF were a) age and gender (diagnosed at age 65 and over, with a 4:1 ratio of males to females); b) race, ethnicity and geographic location (predominantly in Caucasians and in Southern European countries); c) genetic (N-acetyltransferase-2 and glutathione s-transferase M1 gene mutations, which significantly increase the risk for BC); d) occupational, which represent 5%-10% of BC RF; and f) occupations with high BC risk, such as aluminium production, the manufacture of dyes, paints and colourings, the rubber industry and the extraction and industrial use of fossil fuels.
|
23664103 |
2013 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Subjects possessing the NAT2 slow acetylation phenotype and the highest tertile of CYP1A2 scores showed the highest risk for bladder cancer.
|
21480221 |
2012 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The ideas are illustrated using data from a case-control study for bladder cancer involving smoking behaviour and the NAT2 genotype.
|
21432881 |
2011 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
For the NAT2 slow acetylator genotypes, the NAT2*5/*7 diplotype was found to have a 7-fold increased risk to develop bladder cancer (OR = 7.14; 95% CI: 1.30-51.41).
|
21647780 |
2011 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among these women, we found an increased risk of bladder cancer among exclusive users of permanent hair dyes who had NAT2 slow acetylation phenotype (OR = 7.3, 95% CI: 1.6-32.6) compared to never users of dye with NAT2 rapid/intermediate acetylation phenotype.
|
21678399 |
2011 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In summary, these findings are consistent with previous literature suggesting that individual susceptibility to bladder cancer may be modulated by NAT2 polymorphisms, particularly in interaction with relevant environmental exposures such as smoking.
|
20568013 |
2011 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Meta-analysis of the NAT2 associations with bladder cancer showed a highly significant relationship.
|
21037224 |
2011 |